Clinical reference Biomarker Directory
Back to directory

ALD

Emerging

ALD/ABCD1 encodes a peroxisomal fatty acid transporter; its deficiency causes X-linked adrenoleukodystrophy.

Also known as ALD ALDP ABCD1 X-linked adrenoleukodystrophy X-ALD
In plain language

ALD is a rare inherited condition where the body can't properly break down certain fats, which builds up and damages the adrenal glands and, in some boys, the brain. Newborn screening (now in most US states) catches it early using a heel-prick blood test, which matters because early bone marrow transplant can prevent the most severe brain-affecting form if caught in time.

Biomarker & context

ALD (adrenoleukodystrophy) refers to the ABCD1 gene and its protein product (ALD protein, ALDP), a peroxisomal membrane transporter; loss of function causes X-linked adrenoleukodystrophy (X-ALD), a progressive disorder of very long-chain fatty acid (VLCFA) metabolism.

What it indicates

Deficient ALDP function causes VLCFA accumulation in tissues, leading to adrenal insufficiency (Addison's disease) in most affected males and, in about 30-35% of boys, a severe inflammatory cerebral demyelinating form (cerebral ALD) that can progress rapidly if untreated.

Diagnosis & clinical testing

Newborn screening measures C26:0-lysophosphatidylcholine (C26:0-LPC) from a dried blood spot in a two-tier algorithm, followed by ABCD1 gene sequencing to confirm; VLCFA profiling in plasma is used for diagnostic confirmation in symptomatic patients. As of January 2023, 35 US states had added ALD to their newborn screening panels following its 2015 addition to the federal Recommended Uniform Screening Panel (RUSP).

Guiding treatment

Untreated male patients face roughly a 50% chance of adrenal insufficiency before age 10 and a 30-35% chance of developing cerebral ALD, sometimes as early as age 2.75; allogeneic hematopoietic stem cell transplantation can halt cerebral disease progression if performed early, making newborn screening genuinely time-critical rather than just diagnostically convenient. There is currently no validated biomarker to predict which patients will develop the cerebral form or to track its progression, described as "an unmet clinical need" in a 2021 review, though candidate markers (chitotriosidase, GNMPB, C26:0-carnitine) are under active research as of 2024-2025.

Clinical significance

Newborn screening (C26:0-LPC) now covers most US states, enabling time-critical early treatment before irreversible cerebral disease develops.

References
  1. Mares Beltran, C. F., et al. (2024). Newborn Screening for X-Linked Adrenoleukodystrophy (X-ALD). Genes.
  2. Honey, M. I. J., et al. (2021). Molecular Biomarkers for Adrenoleukodystrophy: An Unmet Need. Cells.
  3. PMC. (2023). Diagnosing X-Linked Adrenoleukodystrophy after Implementation of Newborn Screening: A Reference Laboratory Perspective.